AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Pharvaris N.V. (PHVS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

16.80

-0.05 (-0.30%)

At close: Feb 20, 2025, 3:59 PM

16.50

-1.79%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	16.5
Market Cap	907.33M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.73
PE Ratio (ttm)	-6.15
Forward PE	n/a
Analyst	Buy

Ask	17.5
Volume	17,757
Avg. Volume (20D)	67,074
Open	16.79
Previous Close	16.85
Day's Range	16.69 - 17.12
52-Week Range	15.21 - 28.84
Beta	undefined

About PHVS

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 5, 2021

Employees 92

Stock Exchange NASDAQ

Ticker Symbol PHVS

Website https://pharvaris.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for PHVS stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 150.00% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

10 months ago

-7.99%

Pharvaris shares are trading lower after the compa... Unlock content with Pro Subscription

News

1 year ago · zacks.com

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.

1 year ago · investors.com

Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision

Top-notch biotech stock Pharvaris surged Monday after the FDA said it could begin testing a treatment for a swelling disorder in people.

1 year ago · zacks.com

Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal

Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.

1 year ago · investorplace.com

Why Is Pharvaris (PHVS) Stock Up 36% Today?

Pharvaris (NASDAQ: PHVS ) stock is rising higher on Wednesday after the clinical-stage biopharmaceutical company announced an underwritten offering for its shares. That offering includes 11,125,000 sh...

1 year ago · marketwatch.com

Pharvaris shares surge as treatment for severe swelling meets clinical trial goal

Shares of Pharvaris N.V. PHVS, +14.98% jumped 40% premarket on Wednesday after the Switzerland-based company said an investigational drug met its primary goal in a clinical trial for treatment and pre...

1 year ago · seekingalpha.com

Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development

Pharvaris, a clinical-stage company, has reported a cash position of €135 million as of March 31, 2023, indicating an operational runway of approximately 18 months at current loss rates. The company's...